Literature DB >> 31620652

Effect of alcohol consumption on nonalcoholic fatty liver disease.

Gong Weng1, Winston Dunn1.   

Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 26.3% among the US population. A subset of this population exhibits an aggressive histological phenotype, nonalcoholic steatohepatitis (NASH) with ≥ stage 2 fibrosis, which may progress to cirrhosis. The definition of NAFLD excludes excessive alcohol intake, which is well known to cause alcoholic liver disease and will not be discussed here. Most NAFLD clinical trials use ~14 drinks per week as the cutoff for excessive alcohol intake. Alcohol consumption below this threshold, which we define as moderate alcohol consumption, is common in the US. According to the 2012 Behavioral Risk Factor Surveillance System (BRFSS), 56% of the US adult population consume alcohol, but only 8.2% report drinking heavily and 18.3% report binge drinking. The American Association for the Study of Liver Diseases (AASLD) Practice Guidance of 2018 states that there are insufficient data to make a recommendation with regard to moderate alcohol consumption in patients with NAFLD, citing a lack of longitudinal studies that examine the impact of moderate alcohol consumption on disease progression and its extrahepatic harms versus benefits, specifically in individuals with established NAFLD. NAFLD prevalence studies have generally noted a negative correlation between modest alcohol consumption and NAFLD. However, prevalence studies have limited application to patients with established NAFLD who present to the clinic. There can also be many confounding factors, because modest alcohol consumption is also negatively associated with some NAFLD risk factors, and those risk factors may not be adequately adjusted for in analyses. The prevalence of NASH with significant fibrosis (≥ F2) is more important because this is the group that is believed to have progressive disease. Thus, cohort studies of disease progression are more important from the patient's standpoint. Because these patients have already developed NAFLD or NASH, their interest lies in their odds of disease progression if they have moderate alcohol consumption compared to abstinence. It is also noteworthy that cardiovascular disease is the most important cause of death among patients with NAFLD. Moderate alcohol consumption has been associated with a reduction in overall mortality, but mostly in cardiovascular mortality. However, this protective effect has not been demonstrated specifically in patients with NAFLD. 2019 Translational Gastroenterology and Hepatology. All rights reserved.

Entities:  

Keywords:  Nonalcoholic fatty liver disease (NAFLD); alcohol; nonalcoholic steatohepatitis (NASH)

Year:  2019        PMID: 31620652      PMCID: PMC6789297          DOI: 10.21037/tgh.2019.09.02

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  22 in total

Review 1.  How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals?

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Gastroenterology       Date:  2016-01-09       Impact factor: 22.682

Review 2.  Inflammation and metabolic disorders.

Authors:  Gökhan S Hotamisligil
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

Review 3.  Innate immune receptors: key regulators of metabolic disease progression.

Authors:  Chengcheng Jin; Jorge Henao-Mejia; Richard A Flavell
Journal:  Cell Metab       Date:  2013-06-04       Impact factor: 27.287

4.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

Review 5.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

6.  Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease.

Authors:  S Sookoian; D Flichman; G O Castaño; C J Pirola
Journal:  Aliment Pharmacol Ther       Date:  2016-10-24       Impact factor: 8.171

Review 7.  Light alcohol drinking and cancer: a meta-analysis.

Authors:  V Bagnardi; M Rota; E Botteri; I Tramacere; F Islami; V Fedirko; L Scotti; M Jenab; F Turati; E Pasquali; C Pelucchi; R Bellocco; E Negri; G Corrao; J Rehm; P Boffetta; C La Vecchia
Journal:  Ann Oncol       Date:  2012-08-21       Impact factor: 32.976

8.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

9.  Alcohol consumption and mortality among middle-aged and elderly U.S. adults.

Authors:  M J Thun; R Peto; A D Lopez; J H Monaco; S J Henley; C W Heath; R Doll
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

10.  Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease.

Authors:  Winston Dunn; Ronghui Xu; Jeffrey B Schwimmer
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

View more
  5 in total

Review 1.  When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD.

Authors:  Alba Rojano-Toimil; Jesús Rivera-Esteban; Ramiro Manzano-Nuñez; Juan Bañares; David Martinez Selva; Pablo Gabriel-Medina; Roser Ferrer; Juan M Pericàs; Andreea Ciudin
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

Review 2.  Experimental models of metabolic and alcoholic fatty liver disease.

Authors:  Delfin Gerard Buyco; Jasmin Martin; Sookyoung Jeon; Royce Hooks; Chelsea Lin; Rotonya Carr
Journal:  World J Gastroenterol       Date:  2021-01-07       Impact factor: 5.742

3.  Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis.

Authors:  Helen Jarvis; Hannah O'Keefe; Dawn Craig; Daniel Stow; Barbara Hanratty; Quentin M Anstee
Journal:  BMJ Open       Date:  2022-01-04       Impact factor: 2.692

4.  Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China.

Authors:  Qianli Yuan; Huai Wang; Pei Gao; Weixin Chen; Min Lv; Shuang Bai; Jiang Wu
Journal:  Int J Environ Res Public Health       Date:  2022-02-13       Impact factor: 3.390

Review 5.  Considerations for Maximizing the Exercise "Drug" to Combat Insulin Resistance: Role of Nutrition, Sleep, and Alcohol.

Authors:  Mary-Margaret E Remchak; Kelsey L Piersol; Sabha Bhatti; Andrea M Spaeth; Jennifer F Buckman; Steven K Malin
Journal:  Nutrients       Date:  2021-05-18       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.